Adjuvant radiotherapy in breast cancer patients after radical mastectomy or modified radical mastectomy

Abstract

Sun Ying, Zhang Haibo, Yan Ying. Adjuvant radiotherapy in breast cancer patients after radical mastectomy or modified radical mastectomy[J]. Journal of International Oncology, 2016, 43(5): 376-378.

［1］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J Cancer, 2010, 127(12): 2893-2917. DOI: 10.1002/ijc.25516. ［2］惠周光, 张烨, 张江鹄, 等. 2010年与2004年中国大陆地区乳腺癌改良根治术后放疗现状比较［J］. 中华放射肿瘤学杂志, 2012, 21(4): 352-356. DOI: 10.3760/cma.j.issn.10044221.2012.04.018. ［3］ Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2005, 61(5): 1337-1347. DOI: 10.1016/j.ijrobp.2004.08.009. ［4］ Sharma R, Bedrosian I, Lucci A, et al. Presentday locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy［J］. Ann Surg Oncol, 2010, 17(11): 2899-2908. DOI: 10.1245/s104340101089x. ［5］ Yang PS, Chen CM, Liu MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status［J］. Int J Radiat Oncol Biol Phys, 2010, 77(2): 516-522. DOI: 10.1016/j.ijrobp.2009.05.016. ［6］ Hamamoto Y, Ohsumi S, Aogi K, et al. Are there highrisk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?［J］. Breast Cancer, 2014, 21(2): 177-182. DOI: 10.1007/s1228201203697. ［7］王淑莲, 余子豪, 宋永文,等. ER和PR及Her2对改良根治术后腋窝淋巴结阳性乳腺癌放疗疗效的影响［J］.中华放射肿瘤学杂志, 2010, 19(4): 307-310. DOI: 10.3760/cma.j.issn.1673422X.2014.01.021. ［8］谢源福, 吴秀萍, 卓延红, 等. 改良根治术后腋窝淋巴结阳性乳腺癌放疗效果与ER、PR及HER2相关性分析［J］. 国际肿瘤学杂志, 2014, 41(1): 66-69. DOI: 10.3760/cma.j.issn.10044221.2010.04.009. ［9］ Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse［J］. J Clin Oncol, 2010, 28(10): 1684-1691. DOI: 10.1200/JCO.2009.24.9284. ［10］ Al Saeed EF, Ghabbban AJ, Tunio MA. Impact of BMI on locoregional control among saudi patients with breast cancer after breast conserving surgery and modified radical mastectomy［J］. Gulf J Oncolog, 2015, 1(17): 7-14. ［11］ Opp D, Forster K, Li W, et al. Evaluation of bolus electron conformal therapy compared with conventional techniques for the treatment of left chest wall postmastectomy in patients with breast cancer［J］. Med Dosim, 2013, 38(4): 448-453. DOI: 10.1016/j.meddos.2013.08.002. ［12］ Surucu M, Klein EE, MamaluiHunter M, et al. Planning tools for modulated electron radiotherapy［J］. Med Phys, 2010, 37(5): 2215-2224. ［13］ Wright P, Suilamo S, Lindholm P, et al. Isocentric integration of intensitymodulated radiotherapy with electron fields improves field junction dose uniformity in postmastectomy radiotherapy［J］. Acta Oncol, 2014, 53(8): 1019-1026. DOI: 10.3109/0284186X.2014.926027. ［14］章倩, 陈佳艺, 胡伟刚, 等.左侧乳腺癌改良根治术后胸壁和内乳区三维适形和调强放疗计划剂量学研究［J］. 中国临床医学, 2010, 17(3): 445-448. DOI: 10.3969/j.issn.10086358.2010.03.053. ［15］ Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3DCRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison［J］. Radiat Oncol, 2011, 6: 26. DOI: 10.1186/1748717X626. ［16］马金利, 李炯雁, 朱传营, 等. 乳腺癌改良根治术后胸壁和区域淋巴引流区整体化调强放疗剂量学与不良反应分析［J］. 中华放射肿瘤学志, 2012, 21(1): 47-51. DOI: 10.3760/cma.j.issn.10044221.2012.01.014. ［17］周桂霞, 戴相昆, 徐寿平, 等. 乳腺癌术后放疗3种治疗计划的剂量学研究［J］. 中华放射医学与防护杂志, 2010, 30(3): 314-316. ［18］ Nichols GP, Fontenot JD, Gibbons JP, et al. Evaluation of volumetric modulated arc therapy for postmastectomy treatment［J］. Radiat Oncol, 2014, 9: 66. DOI: 10.1186/1748717X966. ［19］ Jia MM, Liang ZJ, Chen Q, et al. Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes［J］. Cancer Biol Med, 2014, 11(2): 123-129. DOI: 10.7497/j.issn.20953941.2014.02.007. ［20］ Darby SC, Mcgale P, Taylor CW, et al. Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries［J］. Lancet Oncol, 2005, 6(8): 557-565. DOI: 10.1016/S14702045(05)702515.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[8]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[9]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[12]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[13]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[14]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[15]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.

Adjuvant radiotherapy in breast cancer patients after radical mastectomy or modified radical mastectomy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments